<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31811140</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Muscleblind acts as a modifier of FUS toxicity by modulating stress granule dynamics and SMN localization.</ArticleTitle><Pagination><StartPage>5583</StartPage><MedlinePgn>5583</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5583</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-13383-z</ELocationID><Abstract><AbstractText>Mutations in fused in sarcoma (FUS) lead to amyotrophic lateral sclerosis (ALS) with varying ages of onset, progression and severity. This suggests that unknown genetic factors contribute to disease pathogenesis. Here we show the identification of muscleblind as a novel modifier of FUS-mediated neurodegeneration in vivo. Muscleblind regulates cytoplasmic mislocalization of mutant FUS and subsequent accumulation in stress granules, dendritic morphology and toxicity in mammalian neuronal and human iPSC-derived neurons. Interestingly, genetic modulation of endogenous muscleblind was sufficient to restore&#xa0;survival motor neuron (SMN) protein localization in neurons expressing pathogenic mutations in FUS, suggesting a potential mode of suppression of FUS toxicity. Upregulation of SMN suppressed FUS toxicity in Drosophila and primary cortical neurons, indicating a link between FUS and SMN. Our data provide in vivo evidence that muscleblind is a dominant modifier of FUS-mediated neurodegeneration by regulating FUS-mediated ALS pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casci</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamurthy</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2552-8912</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Jefferson University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kour</LastName><ForeName>Sukhleen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathy</LastName><ForeName>Vadreenath</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Regenerative Therapies TU Dresden, Technische Universit&#xe4;t Dresden, Fetscherstr. 105, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramesh</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Eric N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrone</LastName><ForeName>Lara</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Regenerative Therapies TU Dresden, Technische Universit&#xe4;t Dresden, Fetscherstr. 105, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Rogan A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-0655-0882</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Stacie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gochenaur</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3682-627X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Krishani</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterneckert</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Regenerative Therapies TU Dresden, Technische Universit&#xe4;t Dresden, Fetscherstr. 105, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gleixner</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Live Like Lou Center for ALS Research, Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Live Like Lou Center for ALS Research, Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruepp</LastName><ForeName>Marc-David</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sini</LastName><ForeName>Antonella M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences (DBS), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuccaro</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences (DBS), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennuto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8634-0767</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences (DBS), University of Padova, Padova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasinelli</LastName><ForeName>Piera</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Jefferson University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Udai Bhan</ForeName><Initials>UB</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. udai@pitt.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. udai@pitt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21- NS100055</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country>International</Country></Grant><Grant><GrantID>R21 NS094921</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS101661</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS081303</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country>International</Country></Grant><Grant><GrantID>R21 NS100055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-NS101661</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country>International</Country></Grant><Grant><GrantID>R21- NS111768</GrantID><Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency><Country>International</Country></Grant><Grant><GrantID>R21 NS111768</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG064940</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055532">SMN Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109271">mbl protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.-</RegistryNumber><NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.-</RegistryNumber><NameOfSubstance UI="C521271">MBOAT1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000123" MajorTopicYN="N">Acetyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055532" MajorTopicYN="N">SMN Complex Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31811140</ArticleId><ArticleId IdType="pmc">PMC6898697</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-13383-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-13383-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013;4:295&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794725</ArticleId><ArticleId IdType="pubmed">24124634</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72:725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">19237701</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole O, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J. Neurol. Neurosurg. Psychiatry. 2008;79:30&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17634215</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur. J. Neurol. 2009;16:745&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, et al. Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch. Neurol. 2009;66:515&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">19364937</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatry. 2011;82:1165&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CT, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J. Epidemiol. 2013;23:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700231</ArticleId><ArticleId IdType="pubmed">23117224</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, et al. Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009. J. Neurol. 2013;260:572&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">23052600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2011;82:623&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot Kevin, Ansorge Olaf. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Human Molecular Genetics. 2006;15(suppl_2):R182&#x2013;R187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987882</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AY, Manley JL. TLS inhibits RNA polymerase III transcription. Mol. Cell Biol. 2010;30:186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798296</ArticleId><ArticleId IdType="pubmed">19841068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Embree LJ, Tsai S, Hickstein DD. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J. Biol. Chem. 1998;273:27761&#x2013;27764.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012;15:1488&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H, et al. binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 1997;110:1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:2899&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373238</ArticleId><ArticleId IdType="pubmed">22454397</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. USA. 2011;108:20881&#x2013;20890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248518</ArticleId><ArticleId IdType="pubmed">22065782</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton M, et al. Matrin 3 binds and stabilizes mRNA. PLoS ONE. 2011;6:e23882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157474</ArticleId><ArticleId IdType="pubmed">21858232</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle JG, et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum. Mol. Genet. 2013;22:1193&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578413</ArticleId><ArticleId IdType="pubmed">23257289</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia R, et al. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol. Neurodegener. 2012;7:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325858</ArticleId><ArticleId IdType="pubmed">22443542</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7:e1002011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048370</ArticleId><ArticleId IdType="pubmed">21408206</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013;342:983&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022187</ArticleId><ArticleId IdType="pubmed">24158904</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson&#x2019;s disease. Physiol. Rev. 2011;91:1161&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">22013209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Trojanowski JQ. Mechanisms of Parkinson&#x2019;s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006;52:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015225</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer W, Kahle PJ. Mechanisms and models of alpha-synuclein-related neurodegeneration. Curr. Neurol. Neurosci. Rep. 2006;6:432&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">16928354</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, et al. Mutations in the 3&#x2019; untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4748&#x2013;4755.</Citation><ArticleIdList><ArticleId IdType="pubmed">23847048</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004;10:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 2010;19:4160&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, et al. Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol. Aging. 2011;32:2323 e2327&#x2013;2323 e2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997923</ArticleId><ArticleId IdType="pubmed">20674093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. Embo J. 2010;29:2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle JG, et al. Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates FUS toxicity. Acta Neuropathol. 2016;131:605&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791193</ArticleId><ArticleId IdType="pubmed">26728149</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Kolaitis RM, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013;153:1461&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760148</ArticleId><ArticleId IdType="pubmed">23791177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey CM, et al. TDP-43 aggregation in neurodegeneration: are stress granules the key? Brain Res. 2012;1462:16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372581</ArticleId><ArticleId IdType="pubmed">22405725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013;154:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Resa. 2010;9:1104&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, Bieri G, Kolaitis RM, Taylor JP, Gitler AD. Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J. Neurosci. 2014;34:8083&#x2013;8097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051967</ArticleId><ArticleId IdType="pubmed">24920614</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J, Taylor JP. Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. Rare Dis. 2013;1:e25200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932941</ArticleId><ArticleId IdType="pubmed">25002999</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell. 2009;36:932&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813218</ArticleId><ArticleId IdType="pubmed">20064460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19:R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 2013;22:2676&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilks N, et al. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol. Biol. Cell. 2004;15:5383&#x2013;5398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC532018</ArticleId><ArticleId IdType="pubmed">15371533</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Huang EJ. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016;1647:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mase G, et al. ALS with variable phenotypes in a six-generation family caused by leu144phe mutation in the SOD1 gene. J. Neurol. Sci. 2001;191:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanadia RN, et al. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302:1978&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14671308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 2010;29:1248&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857464</ArticleId><ArticleId IdType="pubmed">20186122</ArticleId></ArticleIdList></Reference><Reference><Citation>Daughters RS, et al. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. 2009;5:e1000600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719092</ArticleId><ArticleId IdType="pubmed">19680539</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicki DD, et al. Huntington&#x2019;s disease&#x2013;like 2 is associated with CUG repeat-containing RNA foci. Ann. Neurol. 2007;61:272&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilburn B, et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington&#x2019;s disease-like 2 mice. Neuron. 2011;70:427&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107122</ArticleId><ArticleId IdType="pubmed">21555070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoell JI, et al. RNA targets of wild-type and mutant FET family proteins. Nat. Struct. Mol. Biol. 2011;18:1428&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230689</ArticleId><ArticleId IdType="pubmed">22081015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanson NA, Jr., et al. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum. Mol. Genet. 2011;20:2510&#x2013;2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288133</ArticleId><ArticleId IdType="pubmed">21487023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173:706&#x2013;719 e713.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705 e622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, et al. FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation-pi Interactions. Cell. 2018;173:720&#x2013;734 e715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, et al. ALS/FTD mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692 e620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaramuzzino C, et al. Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLoS ONE. 2013;8:e61576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631215</ArticleId><ArticleId IdType="pubmed">23620769</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tradewell ML, et al. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 2012;21:136&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965298</ArticleId></ArticleIdList></Reference><Reference><Citation>Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42:10873&#x2013;10887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176163</ArticleId><ArticleId IdType="pubmed">25183524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation. 2006;74:65&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16533306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, et al. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 2013;16:1383&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc. Natl. Acad. Sci. USA. 2015;112:7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485101</ArticleId><ArticleId IdType="pubmed">26056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats. Hum. Mol. Genet. 2012;21:4602&#x2013;4614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471393</ArticleId><ArticleId IdType="pubmed">22833456</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H, et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 2014;124:981&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938263</ArticleId><ArticleId IdType="pubmed">24509083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu HH, et al. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. Neurobiol. Aging. 2014;35:2822&#x2013;2831.</Citation><ArticleIdList><ArticleId IdType="pubmed">25216585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholl DA. Dendritic organization in the neurons of the visual and motor cortices of the cat. J. Anat. 1953;87:387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1244622</ArticleId><ArticleId IdType="pubmed">13117757</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen EJ, et al. ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum. Mol. Genet. 2013;22:3690&#x2013;3704.</Citation><ArticleIdList><ArticleId IdType="pubmed">23681068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat. Commun. 2015;6:6171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338613</ArticleId><ArticleId IdType="pubmed">25625564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra A, et al. Functional interaction between FUS and SMN underlies SMA-like splicing changes in wild-type hFUS mice. Sci. Rep. 2017;7:2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435706</ArticleId><ArticleId IdType="pubmed">28515487</ArticleId></ArticleIdList></Reference><Reference><Citation>Gama-Carvalho M, et al. Linking amyotrophic lateral sclerosis and spinal muscular atrophy through RNA-transcriptome homeostasis: a genomics perspective. J. Neurochem. 2017;141:12&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S, et al. Evidence that C9ORF72 dipeptide repeat proteins sassociate with U2 snRNP to cause Mis-splicing in ALS/FTD patients. Cell Rep. 2017;19:2244&#x2013;2256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="pubmed">28614712</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, et al. Human iPSC-derived neuronal model of Tau-A152T frontotemporal dementia reveals Tau-mediated mechanisms of neuronal vulnerability. Stem Cell Rep. 2016;7:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032560</ArticleId><ArticleId IdType="pubmed">27594585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science. 2016;353:708&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweizer Burguete A., et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife4, e08881 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, et al. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, et al. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol. 2015;130:525&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS, et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 2015;4:e08881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, et al. Isogenic FUS-eGFP iPSC reporter lines enable quantification of FUS stress granule pathology that is rescued by drugs inducing autophagy. Stem Cell Rep. 2018;10:375&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857889</ArticleId><ArticleId IdType="pubmed">29358088</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt L, et al. Dual inhibition of GSK3beta and CDK5 protects the cytoskeleton of neurons from neuroinflammatory-mediated degeneration in vitro and in vivo. Stem Cell Rep. 2019;12:502&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409486</ArticleId><ArticleId IdType="pubmed">30773488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi VB, Al-Chalabi A. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol. Disord. Drug Targets. 2008;7:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18289027</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr. Med Chem. 2007;14:3185&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho TH, et al. Muscleblind proteins regulate alternative splicing. EMBO J. 2004;23:3103&#x2013;3112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514918</ArticleId><ArticleId IdType="pubmed">15257297</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda A, et al. CUGBP1 and MBNL1 preferentially bind to 3&#x2019; UTRs and facilitate mRNA decay. Sci. Rep. 2012;2:209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250574</ArticleId><ArticleId IdType="pubmed">22355723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ET, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell. 2012;150:710&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428802</ArticleId><ArticleId IdType="pubmed">22901804</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LB, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature. 2008;453:1107&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574630</ArticleId><ArticleId IdType="pubmed">18449188</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes PS, et al. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum. Mol. Genet. 2011;20:2308&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098735</ArticleId><ArticleId IdType="pubmed">21441568</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardaei M, et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum. Mol. Genet. 2002;11:805&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929853</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC302046</ArticleId><ArticleId IdType="pubmed">10970838</ArticleId></ArticleIdList></Reference><Reference><Citation>Squillace RM, Chenault DM, Wang EH. Inhibition of muscle differentiation by the novel muscleblind-related protein CHCR. Dev. Biol. 2002;250:218&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kania A, et al. P-element mutations affecting embryonic peripheral nervous system development in Drosophila melanogaster. Genetics. 1995;139:1663&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1206492</ArticleId><ArticleId IdType="pubmed">7789767</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopenko SN, He Y, Lu Y, Bellen HJ. Mutations affecting the development of the peripheral nervous system in Drosophila: a molecular screen for novel proteins. Genetics. 2000;156:1691&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461357</ArticleId><ArticleId IdType="pubmed">11102367</ArticleId></ArticleIdList></Reference><Reference><Citation>Artero R, et al. The muscleblind gene participates in the organization of Z-bands and epidermal attachments of Drosophila muscles and is regulated by Dmef2. Dev. Biol. 1998;195:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520330</ArticleId></ArticleIdList></Reference><Reference><Citation>Begemann G, et al. muscleblind, a gene required for photoreceptor differentiation in Drosophila, encodes novel nuclear Cys3His-type zinc-finger-containing proteins. Development. 1997;124:4321&#x2013;4331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334280</ArticleId></ArticleIdList></Reference><Reference><Citation>Llamusi B, Artero R. Molecular effects of the CTG repeats in mutant dystrophia myotonica protein kinase gene. Curr. Genomics. 2008;9:509&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694559</ArticleId><ArticleId IdType="pubmed">19516957</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 2004;13:3079&#x2013;3088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanadia RN, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. USA. 2006;103:11748&#x2013;11753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544241</ArticleId><ArticleId IdType="pubmed">16864772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho TH, et al. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J. Cell Sci. 2005;118:2923&#x2013;2933.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc. Trans. 2009;37:1281&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873089</ArticleId><ArticleId IdType="pubmed">19909263</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus S, Bosco DA, Hetz C. Autophagy meets fused in sarcoma-positive stress granules. Neurobiol. Aging. 2014;35:2832&#x2013;2835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324442</ArticleId><ArticleId IdType="pubmed">25444610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama RR, et al. FUS/TLS assembles into stress granules and is a prosurvival factor during hyperosmolar stress. J. Cell Physiol. 2013;228:2222&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000275</ArticleId><ArticleId IdType="pubmed">23625794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzi J, et al. ALS mutant FUS proteins are recruited into stress granules in induced pluripotent stem cell-derived motoneurons. Dis. Model. Mech. 2015;8:755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486861</ArticleId><ArticleId IdType="pubmed">26035390</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi B, et al. The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex. Nucleic Acids Res. 2018;46:11939&#x2013;11951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294556</ArticleId><ArticleId IdType="pubmed">30398641</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford TO, Skolasky RL., Jr. The relationship of SMN to amyotrophic lateral sclerosis. Ann. Neurol. 2002;52:857&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez J, et al. Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology. 2002;59:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427907</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science. 2002;298:1775&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459587</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L, Baccon J, Charroux B, Dreyfuss G. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr. Biol. 2001;11:1079&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">11509230</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G. A functional interaction between the survival motor neuron complex and RNA polymerase II. J. Cell Biol. 2001;152:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193649</ArticleId><ArticleId IdType="pubmed">11149922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L, Charroux B, Dreyfuss G. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc. Natl. Acad. Sci. USA. 1999;96:11167&#x2013;11172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18005</ArticleId><ArticleId IdType="pubmed">10500148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell. 1998;95:615&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845364</ArticleId></ArticleIdList></Reference><Reference><Citation>Reber S, et al. Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants. EMBO J. 2016;35:1504&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946139</ArticleId><ArticleId IdType="pubmed">27252488</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogelj B, et al. Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. Sci. Rep. 2012;2:603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429604</ArticleId><ArticleId IdType="pubmed">22934129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonka S, Sendtner M. Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy. Gene Ther. 2017;24:506&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">28556834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez G, et al. A novel function for the survival motoneuron protein as a translational regulator. Hum. Mol. Genet. 2013;22:668&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">23136128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonka S, Rossoll W, Schrank B, Sendtner M. The role of SMN in spinal muscular atrophy. J. Neurol. 2000;247:I37&#x2013;I42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10795885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Bassell GJ, Rossoll W. Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res. 2012;1462:81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360984</ArticleId><ArticleId IdType="pubmed">22330725</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J. Neurosci. 2011;31:3914&#x2013;3925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070748</ArticleId><ArticleId IdType="pubmed">21389246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder E, et al. The DrosDel collection: a set of P-element insertions for generating custom chromosomal aberrations in Drosophila melanogaster. Genetics. 2004;167:797&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1470913</ArticleId><ArticleId IdType="pubmed">15238529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder E, et al. The DrosDel deletion collection: a Drosophila genomewide chromosomal deficiency resource. Genetics. 2007;177:615&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2013729</ArticleId><ArticleId IdType="pubmed">17720900</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey UB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3:1101&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayser MS, McClelland AC, Hughes EG, Dalva MB. Intracellular and trans-synaptic regulation of glutamatergic synaptogenesis by EphB receptors. J. Neurosci. 2006;26:12152&#x2013;12164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675446</ArticleId><ArticleId IdType="pubmed">17122040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A, McAvoy K, Krishnamurthy K, Trotti D, Pasinelli P. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia. 2018;66:1016&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Edward R. Red/far-red fluorescing DNA-specific anthraquinones for nucl:cyto segmentation and viability reporting in cell-based assays. Methods Enzymol. 2012;505:23&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22289446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>